Magnesium is NOT recommended as a first-line treatment for acute headache based on the most recent 2025 ACP guidelines, which do not include magnesium in their treatment algorithm.
The 2025 American College of Physicians guidelines for acute episodic migraine treatment make no mention of magnesium therapy, instead recommending NSAIDs, acetaminophen, and triptans as primary treatments 1. This represents the highest quality, most recent guideline evidence available and should guide clinical practice.
Current Evidence Status
The absence of magnesium from the 2025 ACP guidelines is notable given that these guidelines specifically evaluated comparative effectiveness of medications for acute migraine treatment. The guideline explicitly states which treatments to use and which to avoid (such as opioids and butalbital), but magnesium is conspicuously absent from both categories 1.
If Magnesium is Still Being Considered
Despite lack of guideline support, if you choose to use magnesium based on older literature or patient preference, here is the protocol derived from FDA labeling and research:
Acute Treatment Protocol (IV Magnesium Sulfate)
Dosing:
- 1 gram IV magnesium sulfate administered over 15 minutes 2, 3
- Dilute to 10% or 20% concentration before administration 2
- Maximum infusion rate: 150 mg/minute (1.5 mL of 10% solution) 2
Administration Details:
- Mix 1 g in 100 mL of 0.9% saline or 5% dextrose
- Infuse over 15 minutes
- Assess response at 15 minutes, 30 minutes, and 2 hours 3
Prophylactic Treatment Protocol (Oral Magnesium)
Dosing:
- 600 mg daily of magnesium dicitrate for migraine prevention 4
- Typically divided into 2-3 doses throughout the day
- Continue for at least 3 months to assess efficacy 4
Critical Caveats and Contradictory Evidence
The Evidence is Mixed and Problematic
Acute treatment studies show conflicting results:
- One small 2001 study (n=30) showed 87% pain-free rate with IV magnesium 3
- However, a 2001 ED trial (n=44) found magnesium worsened outcomes when added to metoclopramide, with a number needed to harm of 4 patients 5
- A 2021 trial (n=157) showed no difference between magnesium, metoclopramide, and prochlorperazine 6
The positive studies have significant limitations:
- Small sample sizes
- Single-blind or unblinded designs
- Lack of standardized outcome measures
- Predominantly female populations
Prophylactic evidence is Grade C (possibly effective) - the lowest level of recommendation 4
Monitoring Requirements
If using IV magnesium:
- Monitor for hypotension and flushing during infusion
- Check patellar reflexes (loss indicates toxicity)
- Monitor respiratory rate (depression indicates toxicity)
- In renal insufficiency: check serum magnesium levels and limit to 20 g/48 hours 2
- Common side effects (86.6% of patients): warmth, flushing, mild hypotension 3
Contraindications from FDA Label
Why This Matters Clinically
The 2025 ACP guideline represents a comprehensive, systematic evaluation of migraine treatments prioritizing patient-centered outcomes including pain relief, functional status, and quality of life 1. The fact that magnesium was not included suggests either:
- Insufficient high-quality comparative effectiveness data
- Evidence showing it is inferior to recommended treatments
- Unfavorable benefit-to-harm ratio compared to alternatives
The guideline explicitly recommends starting with NSAIDs or acetaminophen, escalating to combination therapy with triptans, and only then considering newer agents like CGRP antagonists 1. Magnesium does not appear anywhere in this algorithm.
Practical Bottom Line
Use the 2025 ACP guideline algorithm: Start with NSAIDs (ibuprofen 400-800 mg, naproxen 500-1000 mg) or acetaminophen (1000 mg), add a triptan if inadequate response, and escalate from there 1. Reserve magnesium only for patients who have failed multiple guideline-recommended therapies and specifically request it, understanding the evidence is weak and contradictory.